These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

782 related items for PubMed ID: 25208888

  • 1. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
    Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S.
    Blood; 2014 Oct 23; 124(17):2687-97. PubMed ID: 25208888
    [Abstract] [Full Text] [Related]

  • 2. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S, Dai Y, Pei XY, Grant S.
    Mol Cell Biol; 2009 Dec 23; 29(23):6149-69. PubMed ID: 19805519
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.
    Br J Haematol; 2011 Apr 23; 153(2):222-35. PubMed ID: 21375523
    [Abstract] [Full Text] [Related]

  • 6. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.
    Mol Cancer Ther; 2005 Mar 23; 4(3):443-9. PubMed ID: 15767553
    [Abstract] [Full Text] [Related]

  • 7. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.
    Cancer Res; 2012 Aug 15; 72(16):4225-37. PubMed ID: 22693249
    [Abstract] [Full Text] [Related]

  • 8. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A.
    Cell Death Dis; 2013 May 16; 4(5):e628. PubMed ID: 23681223
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
    Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V, Ginter T, Reichardt S, Liebmann C, Schneider G, Krämer OH.
    Oncotarget; 2012 Jan 16; 3(1):31-43. PubMed ID: 22289787
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF.
    Mol Carcinog; 2013 Feb 16; 52(2):118-33. PubMed ID: 22086447
    [Abstract] [Full Text] [Related]

  • 12. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
    Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S.
    PLoS One; 2014 Feb 16; 9(3):e89064. PubMed ID: 24594907
    [Abstract] [Full Text] [Related]

  • 13. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C.
    J Hepatol; 2012 Jan 16; 56(1):176-83. PubMed ID: 21835141
    [Abstract] [Full Text] [Related]

  • 14. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.
    Cancer Res; 2013 Apr 15; 73(8):2428-34. PubMed ID: 23382048
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
    Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC.
    Oncogene; 2010 Oct 14; 29(41):5619-29. PubMed ID: 20676141
    [Abstract] [Full Text] [Related]

  • 16. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P, Grant S.
    Blood; 2007 Sep 15; 110(6):2092-101. PubMed ID: 17540843
    [Abstract] [Full Text] [Related]

  • 17. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P.
    Blood; 2009 Dec 17; 114(26):5342-51. PubMed ID: 19850739
    [Abstract] [Full Text] [Related]

  • 18. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 19. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.
    Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM.
    Leukemia; 2007 Aug 01; 21(8):1773-82. PubMed ID: 17525724
    [Abstract] [Full Text] [Related]

  • 20. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW, van de Kooij B, Verheij M, Borst J.
    Cell Death Dis; 2012 Aug 09; 3(8):e366. PubMed ID: 22875003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.